Results 201 to 210 of about 4,259,087 (330)
ABSTRACT Somatostatin receptors (SSTR) mediate the antiproliferative, antisecretory, and proapoptotic effects of somatostatin and its synthetic analogs. Their surface expression on neuroendocrine tumor (NET) cells is required for somatostatin analog therapy and radiopharmaceutical therapy (RPT).
Neeraj Kumari +10 more
wiley +1 more source
From bench to bedside: combining HDAC inhibitors with standard therapies in rhabdomyosarcoma treatment. [PDF]
Macrì E +4 more
europepmc +1 more source
ABSTRACT Purpose To evaluate lesion severity distribution in ischaemic brain lesions in spontaneously hypertensive rats (SHR) subjected to 90‐min transient middle cerebral artery occlusion (tMCAO), and to determine whether epigenetically based neuroprotection modifies lesion severity profiles using a voxel‐wise T2 distribution framework.
Andrea Díaz‐Pérez +3 more
wiley +1 more source
Cellular Target Engagement and Dissociation Kinetics of Class I-Selective Histone Deacetylase (HDAC) Inhibitors. [PDF]
Honin I +6 more
europepmc +1 more source
Clostridioides difficile toxins TcdA and TcdB enter intestinal epithelial cells (IECs) via specific receptors, disrupt tight‐junction integrity and activate PI3K/Akt/mTOR signalling, promoting inflammasome assembly and IL‐1β release. Toxin‐induced IEC apoptosis further weakens the epithelial barrier.
Sisi Zhang +7 more
wiley +1 more source
HDAC inhibitors as anticancer drugs: chemical diversity, clinical trials, challenges and perspectives. [PDF]
Abdallah AE.
europepmc +1 more source
Targeting glioblastoma with HDAC inhibitors: insights into hydroxamic acid-based therapeutic strategies. [PDF]
Pai P +12 more
europepmc +1 more source
Organoids in pediatric cancer research
Organoid technology has revolutionized cancer research, yet its application in pediatric oncology remains limited. Recent advances have enabled the development of pediatric tumor organoids, offering new insights into disease biology, treatment response, and interactions with the tumor microenvironment.
Carla Ríos Arceo, Jarno Drost
wiley +1 more source
Pharmacological chromatin remodeling enhances response to estrogen therapy in ER+ breast cancer
Estrogen therapy elicits clinical benefit in ~ 30% of patients with endocrine‐resistant estrogen receptor (ER)‐positive breast cancer. Based on findings that ER transcriptional activation underlies response to estrogen therapy, we tested the effects of epigenetic dysregulation via pharmacological inhibition of histone deacetylases (HDACi).
Anneka L. Johnson Thomas +16 more
wiley +1 more source

